Vivoryon Therapeutics N.V. to Present at Upcoming Investor Conference
07 nov. 2023 01h00 HE
|
Vivoryon Therapeutics N.V.
Vivoryon Therapeutics N.V. to Present at Upcoming Investor Conference Halle (Saale) / Munich, Germany, November 7, 2023 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7)...
Vivoryon Therapeutics N.V. Provides Comprehensive Progress Report for Ongoing Varoglutamstat Clinical Program Following R&D Event and VIVA-MIND DSMB Dose Decision
26 oct. 2023 01h00 HE
|
Vivoryon Therapeutics N.V.
Vivoryon Therapeutics N.V. Provides Comprehensive Progress Report for Ongoing Varoglutamstat Clinical Program Following R&D Event and VIVA-MIND DSMB Dose Decision Both VIVIAD and VIVA-MIND...
Vivoryon Therapeutics N.V. Reports Positive Outcome from Independent Data Safety Monitoring Board with Unanimous Decision for VIVA-MIND U.S. Study of Varoglutamstat in Alzheimer’s Disease to Proceed at Highest Investigated Dose
23 oct. 2023 01h00 HE
|
Vivoryon Therapeutics N.V.
Vivoryon Therapeutics N.V. Reports Positive Outcome from Independent Data Safety Monitoring Board with Unanimous Decision for VIVA-MIND U.S. Study of Varoglutamstat in Alzheimer’s Disease to Proceed...
Vivoryon Therapeutics N.V. Shares Highlights from Virtual R&D Event with Key Opinion Leaders
17 oct. 2023 09h32 HE
|
Vivoryon Therapeutics N.V.
Vivoryon Therapeutics N.V. Shares Highlights from Virtual R&D Event with Key Opinion Leaders Multiple KOLs highlight varoglutamstat pathology, clinical development and clinical applicability of...
Vivoryon Therapeutics N.V. Announces Virtual R&D Event with Key Opinion Leaders and Upcoming Conference Participation
05 oct. 2023 01h00 HE
|
Vivoryon Therapeutics N.V.
Vivoryon Therapeutics N.V. Announces Virtual R&D Event withKey Opinion Leaders and Upcoming Conference Participation Halle (Saale) / Munich, Germany, October 5, 2023 – Vivoryon Therapeutics N.V....
Vivoryon Therapeutics N.V. Extraordinary General Meeting Approved Appointment of New Executive Directors to the Board
15 sept. 2023 07h57 HE
|
Vivoryon Therapeutics N.V.
Vivoryon Therapeutics N.V. Extraordinary General MeetingApproved Appointment of New Executive Directors to the Board Halle (Saale) / Munich, Germany, September 15, 2023 – Vivoryon Therapeutics N.V....
Vivoryon Therapeutics N.V. Reports H1 2023 Financial Results and Highlights Operational Progress
07 sept. 2023 01h00 HE
|
Vivoryon Therapeutics N.V.
Vivoryon Therapeutics N.V. Reports H1 2023 Financial Results and Highlights Operational Progress Both VIVIAD and VIVA-MIND studies on track; final data from VIVIAD expected in Q1/2024, and a...
Vivoryon Therapeutics N.V. to Report Half Year 2023 Financial Results and Operational Progress on September 07, 2023
31 août 2023 01h00 HE
|
Vivoryon Therapeutics N.V.
Vivoryon Therapeutics N.V. to Report Half Year 2023 Financial Results and Operational Progress on September 07, 2023 Halle (Saale) / Munich, Germany, August 31, 2023 - Vivoryon Therapeutics N.V....
Vivoryon Therapeutics N.V. Extraordinary General Meeting to Confirm New Executive Director Appointments to the Board, Being Held on September 15, 2023
04 août 2023 17h35 HE
|
Vivoryon Therapeutics N.V.
Vivoryon Therapeutics N.V. Extraordinary General Meeting to Confirm New Executive Director Appointments to the Board, Being Held on September 15, 2023 Halle (Saale) / Munich, Germany, August 4, 2023...
Vivoryon Therapeutics N.V. Announces Proposed Appointment of Dr. Frank Weber as Chief Executive Officer
04 août 2023 17h30 HE
|
Vivoryon Therapeutics N.V.
Vivoryon Therapeutics N.V. Announces Proposed Appointment of Dr. Frank Weber as Chief Executive Officer Frank Weber, MD, current Chief Medical Officer (CMO), promoted to Chief Executive Officer...